October 19, 2022 — For men and women, the risk factors for cardiovascular disease are largely the same, an extensive global study involving University of Gothenburg researchers shows. 

AI & Engineered Tissues for Cardiac Disease Therapeutics Conference

October 18, 2022 —  Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective yesterday. In his more than 30 years in the medical technology arena, Casciaro has developed a track record of success leading and growing both private and public companies, from clinical through commercial phases, and from fundraising through acquisitions.

October 18, 2022 —  The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its Impella Low

October 17, 2022 —  A national study suggests that risk factors for cardiovascular disease, such as age, smoking and diabetes – not preexisting heart disease – are the main contributors to death and poor outcomes for critically ill COVID-19 patients. 

October 17, 2022 —  Global Health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs, statins and aspirin widely in the form of a single pill, also known as the polypill, say two leading cardiologists in a commentary published in The Lancet.

October 17, 2022 —  Allegheny Health Network’s (AHN) Cardiovascular Institute announced the expansion of its nationally recognized thoracic surgery program to AHN Wexford Hospital, marking the full-service hospital’s most recent milestone in providing access to the highest level of care to patients living in communities north of Pittsburgh.

October 18, 2022 — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of $35M and upfront closing payment of $200M, regulatory achievement milestones of up to $125M and commercial milestones of up to $775M through 2029 for a total consideration of up to $1.135

Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late-breaking scientific session at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2022 Annual Symposium in Boston, MA.

October 17, 2022 — Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late-breaking scientific session at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2022 Annual Symposium in Boston, MA.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now